About Rodeo Therapeutics
Rodeo Therapeutics is a company based in Seattle (United States) founded in 2017 by Stanton Gerson and Sanford Markowitz was acquired by Amgen in March 2021. Rodeo Therapeutics has raised $14.85 million across 2 funding rounds from investors including Amgen, AbbVie and Lilly. Rodeo Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others.
- Headquarter Seattle, United States
- Founders Stanton Gerson, Sanford Markowitz
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Rodeo Therapeutics
Unlock access to complete
Unlock access to complete
Software Development Team
208 people
Leadership Team
193 people
Sales and Marketing
82 people
Data Analysis and Operations Team
73 people
Senior Team
66 people
Operations Team
64 people
Product Management Team
55 people
Scientific Team
34 people
Unlock access to complete
Funding Insights of Rodeo Therapeutics
Rodeo Therapeutics has successfully raised a total of $14.85M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8.95 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rodeo Therapeutics
Rodeo Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Amgen, AbbVie and Lilly.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage investments focused VC firm
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Venture capital services are offered for early-stage biotech companies.
|
Locked | Locked | Locked |
Investor details for Rodeo Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rodeo Therapeutics
Investment portfolio details for Rodeo Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rodeo Therapeutics
Detailed financials for Rodeo Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rodeo Therapeutics Comparisons
Peer comparison for Rodeo Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rodeo Therapeutics
Rodeo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Oral peptide therapeutics are developed for gastrointestinal diseases.
|
|
| Locked | Locked | Locked |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| Locked | Locked | Locked |
Developer of immunomodulators for cancer and auto-immune diseases
|
|
| Locked | Locked | Locked |
Therapeutics for epithelial-based diseases are developed and targeted.
|
|
| Locked | Locked | Locked |
Biotherapeutics for auto-immune disorders and type-1 diabetes are developed.
|
Detailed competitors of Rodeo Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rodeo Therapeutics
Complete news archive for Rodeo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rodeo Therapeutics
Rodeo Therapeutics was founded in 2017.
Rodeo Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Rodeo Therapeutics is a funded company, having raised a total of $14.85M across 2 funding rounds to date.
Rodeo Therapeutics, a preclinical-stage biotech company, is focused on first in class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration. The company is developing 15-PGDH (prostaglandin-degrading enzyme) inhibitors for the treatment of inflammatory bowel disease and promoting blood cell reconstitution following the bone marrow transplant (preclinical). Preclinical studies published in Science have shown that increasing PGE2 through inhibition of a prostaglandin-degrading enzyme (15-PGDH) accelerates hematopoietic stem cell reconstitution following bone marrow transplant, protects against colitis and promotes liver regeneration in a variety of animal models.
Rodeo Therapeutics's top competitors include Aclaris Therapeutics, Protagonist Therapeutics and Samsung Bioepis.
Rodeo Therapeutics has 10 investors. Key investors include Amgen, AbbVie, Lilly, WuXi AppTec, and Arch Venture Partners.